creatic development must include both the resolution of the endocrine and exocrine tissues, as well as the multiple cell types contained in each tissue. In the classic description of pancreatic morphogenesis, the molecular mechanisms underlying dorsal and ventral pancreatic development are similar, islet and acinar cells derive from ductal cells, and the hormoneexpressing cells initially detected in the nascent pancreatic buds are precursors for later endocrine cells. However, the results of recent studies have revised this original framework considerably.
Pedro Luis Herrera Merino (Geneva, Switzerland) provided a clear picture of pancreas morphogenesis. During embryogenesis, the pancreatic endoderm is exposed sequentially to distinct mesodermal cell populations. The dorsal endoderm contacts the notochord, aorta, and pancreatic mesenchyme. The ventral endoderm lies adjacent to the septum transversum and cardiogenic mesoderm and then contacts ventral veins and mesenchyme. Pancreatic morphogenesis begins in response to signals from these mesodermal tissues and is orchestrated by a cascade of transcription factors expressed by specific cells in a specific sequence. Two essential homeodomains contain the transcription factors Hlxb9 and Pdx1/Ipf1, which are expressed before bud formation (∼E9.5). However, Hlxb9 expression becomes negative within 2 days of bud formation and then reappears in differentiating islet cells. Pdx1 expression continues in duodenal and dorsal stomach epithelium (E11.5), and in the absence of Pdx1, growth and morphogenesis of the bud epithelia is suspended. The inductive signals FIGURE 1. Morphogenesis of the mouse pancreas and the expression of key genes during embryonic development. Table 1 summarizes the role of each individual gene. FGF4, fibroblast growth factor 4; FGF2, fibroblast growth factor 2; Shh, Sonic hedgehog. Graphics adapted with permission from Curr Opin Genet Dev. 2002; 12:540-547. required for the dorsal and ventral foregut endoderm to develop into the pancreas are provided by adjacent mesodermal structures, such as the notochord, dorsal aorta, cardiogenic mesoderm, and septum transversum. The expression of Sonic hedgehog (SHH) in a region of the foregut is repressed by the notochord signal, leading the dorsal foregut endoderm to become the pancreas, while the absence of the repressor signal leads to intestine formation.
The expression of key pancreatic transcription factors such as Pdx1, Pbx1, PTF1-p48, and Neurogenin 3 (Ngn3) is required throughout development of the pancreas. Although Pdx1 expression is not essential for the initiation of pancreatic budding from the endoderm, the expression of Pdx1 and Ngn3 is essential for regulating pancreatic morphogenesis and differentiation. Pbx1 is a member of the TALE class of homeodomain transcription factors that regulate the activity of other homeobox factors and is essential for normal pancreatic development and function. PTF1-p48 is the pancreas-specific subunit of the heteromeric bHLH protein complex PTF1 that binds and activates the transcriptional enhancers of the acinar hydrolytic enzyme genes. The major role of p48 may be in acinar cell differentiation that begins at ∼E13.5. However, p48 is expressed as early as E9.5 and has been shown to play a more fundamental role in endocrine and exocrine pancreatic development. In the nascent buds (E9.5-10), glucagon-and insulinpositive cells are detected by immunostaining, but whether these cells are islet precursors has yet to be determined. Proliferation of the pancreatic epithelium and mesenchyme branching, morphogenesis, and fusion of the dorsal and ventral buds occur by E12.5 and produce an epithelial tubular complex containing the precursor cells for islets, acini, and ducts. The first cells differentiating in the embryonic pancreas are endocrine cells (glucagon-positive cells) followed by insulinpositive cells. These cells are found in duct epithelia, migrate into the interstitium, and form endocrine cell clusters. Morphogenesis of mouse pancreas is diagrammatically presented in Figure 1 , [12] [13] [14] [15] and genes expressed during pancreas development and their possible roles are summarized in Table 1 .
Using different cell tracing approaches, Dr. Herrera's group has delineated pancreatic endocrine cell lineages. Using the Cre/Lox approach, which permits the detection of the descendants after they no longer express the reporter genes, the group has shown that (1) all pancreatic cells derive from cells expressing Pdx1, (2) islet cells derive from the cells expressing Ngn3 and Pax6, while exocrine cells derive from cells expressing p48, (3) glucagon-positive cells derive from a lineage different from insulin-positive cells, and early glucagon-positive cells are not the precursors of ␤ cells, and (4) early pancreatic polypeptide-positive cells are necessary for ␤ cell development. Interestingly, early glucagon-positive cells also express Pdx1, but adult glucagon-positive cells do not.
Michael S. German (San Francisco, CA) discussed ␤ cell differentiation in transgenic mice, which has been used for determination of the origin of pancreatic endocrine cells. He has shown that endocrine cells derive from cells positive for Pdx1 and Ngn3, although Ngn3 expression occurs only during embryogenesis. Ngn3 turns on several genes, including PAX4 and NKX2. 2 .
The research goal of Christopher V. E. Wright and his colleagues (Nashville, TN) is to achieve a complete understanding of the gene networks and cell interactions underlying pancreas differentiation and maintenance as reflected by the title of his presentation "Global and Tissue-Specific Requirements for Transcription Factors in Pancreas Development." Using Cre/LoxP-mediated gene inactivation and lineage tracing, this group has shown that Pdx1 is required for outgrowth and differentiation of pancreatic buds. Pdx1 is required in adult insulin-producing cells, and a low level of Pdx1 expression (relative to ␤ cells) is essential for differentiation in exocrine cells. The PTF-p48b gene, which is required in adult acinar cells, is expressed in a subregion of the endodermal Pdx1-expression domain. Their recent studies using genetic recombination-based lineage tracing in normal tissue and after gene inactivation have shown that PTF-p48 is not exocrine specific but expressed in progenitors of ducts, islets, and acinar cells, and he speculated that these cells may be multipotent stem cells. Inactivation of PTF1-p48 gene causes pancreatic precursors to convert to duodenal epithelium. Thus, PTF1-p48 must be an essential molecular trigger for acquisition of pancreas fate from the foregut.
Islet morphogenesis and stem-cell markers were also discussed by Luc Bouwens (Brussels, Belgium). He suggested that mammalian cells retain the capacity for dedifferentiation, cell cycle reentry, and transdifferentiation. His talk was based on the observation of islet neogenesis in the rat pancreas at the late gestation stage and the duct-ligated pancreas in adults. Distinct findings in the duct-ligated pancreas of rats treated with gastrin included the appearance of a high number of single insulin-positive cells and the presence of cell clusters formed by a few insulin-positive cells, which may indicate islets budding from precursors or islet neogenesis. In the surviving acinar cells, a metaplastic conversion took place after duct ligation to become regenerative epithelial cells. In culture, acinar cells lose the ability to produce acinar-specific molecules, transdifferentiate into a duct-like phenotype, and display fetal pancreatic cell characteristics. Duct cells and dedifferentiated exocrine cells have shown far greater proliferative potential than islet cells, and their plasticity, as Dr. Bouwens speculated, plays a significant role in the rapid increase in islet numbers in the pancreas during late gestation and duct ligation-mediated islet regeneration. He also speculated that enzymatic dissociation of pancreatic tissue may have similar metaplasia-inducing effects as seen in duct ligation. He showed data demonstrating that nestin is expressed in the pancreatic mesenchymal "stellate"-type cells and neovascular and/or angiogenic endothe- Key role in pancreas morphogenesis and in maintaining the insulin production and glucose-sensing system in ␤ cells Pancreatic agenesis; ␤ cell specific inactivation of Pdx1 led to loss of ␤ cell phenotype and diabetes
Pbx1
Interacts with Pdx1 and the Pdx1/Pbx1 complexes; necessary for the expansion of the pancreatic buds but not for the specification of the different pancreatic cells Impairment of both endocrine and exocrine portions of the pancreas
HNF6
Specifies pancreatic epithelial cells; is necessary for the normal increase in endocrine cells; stimulates Ngn3 gene expression
Exocrine portion of the pancreas was normal; on E9.5, glucagon expression was standard but on E12.5 insulin+ cells were absent and glucagon+ cell number decreased by 85%; after birth, ␣, ␤, ␦, and PP cells were markedly reduced; at birth, Ngn3 expression lessened and the pancreas showed abnormal architecture; mice were hypoglycemic at birth and then became glucose intolerant Pax4
Differentiation of ␤ and ␦ cells. Not necessary for the development of early insulin+ cells, but required for ␤ and ␦ cell maturation and maintenance.
On E13.5, insulin+ cells were negative and markers for ␤ cells were absent Mice appeared normal at birth but died in 3-5 days; in the pancreas, mature ␤ and ␦ cells were absent and ␣-cell numbers increased Pax6
Required for the regulation of islet cell count, islet morphology, and islet hormone synthesis levels.
In the pancreas, ␣ cells were absent; ␤, ␦, and PP cells were markedly reduced and islets were disorganized The pancreas of Pax4 and Pax6 double mutant mice contained no mature endocrine cells Nkx2. 2 Required for terminal differentiation of ␤ cells and maintenance of Nkx6.1
Arrest of ␤ cell differentiation and no maturation of ␤ cells; decreased ␣ and PP cell count and incomplete differentiation of ␤ cells; some ␤ cell markers such as IAPP and PC1/3 were also present; Nkx6.1 were apparent but disappeared by E18.5
Isl1
Required for early formation of the pancreas and differentiation of islet cells but not for exocrine cells
No formation of the dorsal pancreatic mesoderm, failure of exocrine cell differentiation in the dorsal pancreatic bud, and loss of differentiated islet cells Ngn3
Involved in islet cell development of endocrine precursors but turns off before the final differentiation At birth, the −/− mouse pancreas contained an exocrine portion but no endocrine cells The pancreas of mice overexpressing Ngn3 showed a marked increase of endocrine cell formation at very early stage of development (E8.5) NeuroD1/BETA2 Important in the expression of differentiated endocrine cell product and for insulin gene transcription; it is induced by Ngn3
Reduction of ␣ (40%), ␤ (75%), and ␦ (20%) cells at birth due to increased apoptosis; the remaining ␤ cells continued to produce insulin
PTF1-p48
Required for epithelial cells of the bud to commit to become the pancreas; in later stages of development, it is required for exocrine development
Lack of exocrine portion of the pancreas; endocrine cells formed but reside in the spleen
Nkx6.1
Necessary for expansion and final differentiation of ␤-cell progenitors Insulin+ cells were present at the same level as wild type until E12.5 Afterward, ␤-cell numbers severely decreased, but ␣, ␦, and PP cell count remained normal; Ngn3+ progenitor cells were present, but insulin+ cells reduced by 95% *Adult = after birth. The basic helix-loop-helix (bHLH) family.lium of fetal and adult regenerated rat pancreas, but not in pancreatic epithelial cells, including both ducts and islets.
Cell-cell and cell-matrix interactions play a critical role in the morphogenesis of islets. Vincenzo Cirulli (LaJolla, CA) reported that ␣v␤3 and ␣v␤5 integrins, which were known to coordinate epithelial cell adhesion and motility, were expressed in pancreatic duct cells and clusters of undifferentiated epithelial cells emerging from the duct. His team detected, in vitro, the presence of these molecules at the tip of actin filaments. Blocking these molecules interferes with cell spreading and migration. In vivo, blocking the activities of ␣v␤3 and ␣v␤5 integrins inhibited islet formation, decreased the number of ␤ cells, and increased the number of ␣ cells. These results indicate that integrin molecules may also signal cell differentiation. Their recent studies have focused on diffusible factors, such as cytokines, chemokines, and growth factors that could be stored in the extracellular matrices. Netrin-1 is a secreted protein that exhibits chemoattractant properties in the developing central nervous system, where it mediates axon guidance. Netrin-1 is found to be expressed by a discrete population of epithelial cells in the fetal pancreas, to bind efficiently to extracellular matrix components such as collagen IV, and to mediate cell migration through ␣6␤4 and ␣3␤1 integrins, which act as novel receptors for Netrin-1 in epithelial cells. Based on these findings, he suggested the existence of integrin/Netrin-1 interactions as novel adhesive and/or migratory cues, possibly regulating developmental processes in the mammalian pancreas.
Gladys Teitelman (Brooklyn, NY) has used an insulintreated streptozotocin (STZ) diabetic mouse model to characterize islet-derived multipotential stem and/or progenitor cells. She discovered that the restoration of euglycemia by insulin injections immediately following ␤ cell depletion by STZ dramatically increases ␤ cell neogenesis. In this model, new ␤ cells are generated from 2 different sets of intraislet ␤ cell precursors expressing embryonal traits: 1 cell lineage expressed somatostatin and Pdx1 and the other GLUT2. Dr. Teitelman speculated that after STZ exposure, both ␦ and ␣ cells revert to an immature phenotype, characteristic of these cells during development. Thus, ␦ cells resume Pdx1 expression, initiate insulin expression, downregulate somatostatin synthesis, and become monospecific ␤ cells, while ␣ cells start to express GLUT2. In addition, the GLUT2 expression is presumably activated in precursor cells residing in the islets as they differentiate into ␤ cells. Discrepancy between her speculation and the findings by other investigators as to whether glucagon-positive cells are precursors of ␤ cells was not resolved.
Construction of a functional genomic library enriched in endocrine transcripts expressed during fetal development is an essential tool in these areas of research. Klaus H. Kaestner (Philadelphia, PA) represented the NIDDK-sponsored consortium entitled "Functional Genomics of the Developing Endocrine Pancreas" and summarized its activities over the past 3 years. The 3 major objectives of the consortium are (1) to develop and sequence cDNA libraries of mouse and human endocrine pancreas, (2) to construct cDNA microarrays enriched for clones expressed in the endocrine pancreas, and (3) to develop bioinformatics tools for the diabetes community (exemplified in the Endocrine Pancreas Consortium Database, EPConDB (www.cbil.upenn.edu/EPConDB/). The EPConDB website contains information on the libraries and sequences generated by the consortium, as well as data from microarray experiments. The library construction makes use of the Ngn3 knockout mice, which lack all endocrine cells, to construct a subtracted library enriched in endocrine transcripts expressed during fetal development. Unique nonredundant mRNA assemblies identified so far were 7,700 in mice and 8,000 in humans. A pilot microarray of close to 4000 unique elements was constructed based on a bioinformatics approach, and a combined pancreas-enriched microarray with more than 11,000 elements is currently in the process of printing. The full-length sequencing of the 7700 nonredundant mouse pancreas sequences and high-throughput expression profiling of pancreasenriched transcripts are also in progress. Information on the libraries, sequences, and data from microarray experiments are available on the EPConDB website.
RECENT DEVELOPMENT IN ␤-CELL INSULIN SYNTHESIS AND SECRETION RESEARCH
The conversion of proinsulin to insulin occurs at the 2 processing sites marked by pairs of basic amino acids, primarily after packaging into insulin secretory granules.
3 Howard W. Davidson (Denver, CO) presented new findings on enzymes involved in the processing of proinsulin to insulin. Proinsulin processing requires 3 enzymes: prohormone convertase 1 (PC1), prohormone convertase 2 (PC2), and carboxypeptidase E (CPE). Processing is essentially restricted to nascent and maturing secretory granules. PC1-mediated cleavage of the B-C junction (Lys-Thr-Arg↓Glu-Ile) likely occurs first. The exposed basic residues are then removed by CPE and subsequently cleaved by PC2 at the A-C junction (Leu-GlnLys-Arg ↓Gly-Ile) to release the mature hormone. The ionic compositions of the various secretory compartments and the biochemical properties of the enzymes regulate this order. Thus, PC1 is activated in the endoplasmic reticulum, but is essentially nonfunctional prior to delivery to the trans-Golgi network/nascent granule, due to a higher pH and lower calcium ion concentration of the earlier compartments, and possibly by binding of the propeptide or of pro SAAS, an endogenous PC1 inhibitor expressed in neuroendocrine cells. The activation of PC2 is prevented by the requirement of an acidic pH for its autoactivation and by a noncompetitive inhibitor, pro7B2. Furthermore, PC2 binding to the A-C junction likely requires some structural alteration of the precursor.
Peter Arvan (Bronx, NY) provided a comprehensive review on secretory protein trafficking from post-Golgi secre-tory protein packaging to exocytosis, including a model termed the "cisternal maturation model of the Golgi complex" and the "sorting-by-retention" hypothesis. 4 GH4C1 cells lack PC1 and PC2. By inducing stable PC1 expression in the GH4C1 cells, his group has shown that PC1 is involved in storing insulin in secretory granules. The yeast prohormone convertase Kex2p mediates intracellular retention of insulin through endoproteolysis that express recombinant insulincontaining fusion protein. Dr. Arvan's team found a family of genes in yeast that affect the activity of Kex2p processing of proproteins in the secretory pathway. They found evidence that a number of soluble secretory proteins enter the stimulusdependent insulin secretory pathway of ␤ cells, indicating a relative lack of selectivity at this step. Syntaxin 6 (Syn6), a SNARE protein involved in vesicle fusion, is localized to immature secretory granules (and endosomes), but not mature ␤ cell granules, and is known to be required for mature granule biogenesis. To examine the role of Syn6 either full-length Syn6 or a dominant-negative membrane-anchorless construct, Syn6t, was used to express the gene in INS-1 cells using an ecdysone-inducible gene expression method. The expression of Syn6t inhibited the lysosomal delivery via the endocytic pathway. However, Syn6t expression impaired neither secretory granule formation, proinsulin processing, nor secretagogue-stimulated ␤-granule exocytosis. These results have indicated that the Syn6 SNARE protein fulfills a specific role in endosomal maturation but plays a less important and indirect role in the regulated, constitutive, and lysosomal biogenesis pathway.
Guy A. Rutter (Bristol, UK) presented new imaging approaches that permit monitoring dynamic molecular events taking place in single living cells. Gene expression and insulin secretion were monitored using bioluminescent probes, such as firefly luciferase, which were inserted into cells by microinjection or by adenoviral technology. Dr. Rutter showed that these methods had potential to turn a single cell into a living "test tube" by achieving specific "knockout or knockdown" of key signaling elements. He stated that quantitative measurements of mRNA levels at a single cell level would also become feasible before long. The key finding in this field over the past 5 years is that added insulin can mimic the effects of glucose to stimulate expression of the preproinsulin (PPI) gene. Consequently, insulin secretion plays a central role in the activation of gene expression by glucose in the ␤ cells. Hyperglycemia stimulates the transcription of the PPI gene and of at least 20 other genes in ␤ cell to ensure normal insulin production and release. In single ␤ cells, PPI promoter induction is suppressed if insulin secretion is blocked, whereas the blockade of promoter induction is reversed if insulin is replaced in the cells. Inactivation of the insulin receptor leads to a significant suppression of glucose and/or insulin stimulation of the PPI promoter with no evident effect on the IGF-1 receptor expression. Inactivation of IGF-1 receptor has no impact on glucose and/or insulin stimulated PPI gene transcription, demonstrating the specificity for insulin. Inhibition of type I PI 3K activity by overexpression of the regulatory ␤p85 subunit blocks glucoseinduced expression of the PPI and liver type pyruvate kinase promoters. Expression of constitutively active PI 3K catalytic subunits mimics the effect of glucose on PPI promoter activity. Their results suggest that the effects of glucose may be mediated in part through an autocrine action of released insulin on ␤ cell insulin receptors.
Insulin receptor signal transduction plays a critical role in regulating ␤ cell function, notably the acute first-phase insulin release in response to glucose. Michel Bernier (Baltimore, MD) presented evidence that ␤ cell insulin resistance may be related to abnormal regulation of tyrosine phosphorylation events associated with an alteration in protein tyrosine phosphatase (PTPase) expression and/or activity. A subset of PTPases is implicated in the regulation of insulin signaling machinery in ␤ cells, including regulation of the insulin receptor and insulin receptor substrates (IRS)-1 and -2. Insulin binding to the ␤ cell insulin receptor triggers the receptor autophosphorylation, leading to subsequent phosphorylation of many cellular substrates on tyrosine residues including IRS-1 and IRS-2. The formation of competent signaling complexes at the plasma membrane then initiates a sequence of phosphorylation events critical for processes as diverse as metabolism, protein synthesis, cell growth and proliferation, and resistance to apoptosis. In vivo, various types of tissue-specific knockout mice have shown the importance of insulin signaling at the level of the ␤ cells for glucose-stimulated insulin secretion, indicating insulin resistance in ␤ cells related to abnormal regulation of tyrosyl dephosphorylation. He suggested that the design of selective PTPase inhibitors might be of therapeutic value in the management of disorders associated with insulin resistance. PTPases present in the ␤ cells, and their function and specificity were also discussed.
NEW FINDINGS IN ISLET-CELL SIGNALING NETWORK
Insulin secretion is mediated by complex signal transduction events and unraveling this signaling system is eminently important for understanding ␤ cell biology. John D. Scott (Portland, OR) pointed out that a fundamental principle of signal transduction is that parallel signaling pathways are assembled from a common repertoire of enzymes, and are able to propagate diverse physiological responses. The key feature of this mechanism is that separate signaling pathways are organized into localized transduction units, each tailored to respond optimally to a particular signal. One of the key events is protein-protein interaction maintained by anchoring adapters and scaffolding molecules that provide molecular glue. Such proteins hold signal transduction units together. Dr. Scott discussed some new experimental tools used by his team. They combine both gene-array and molecular biologic technologies
Advances in Islet Cell Biology in gene expression analysis for the dissection and manipulation of intracellular molecular events and the disruption or inhibition of protein anchoring. These types of highly sophisticated and broad ranging biochemical approaches were useful tools for their investigations in dissecting scaffolding molecules to develop functional domains. He concluded that this type of investigation should provide answers for biologic questions related to signaling network and contribute to the understanding of dynamic biologic activities. Ravi Iyengar (New York, NY) utilizes both computational models and laboratory experiments and integrates the results to unravel complex cellular events. He demonstrated the value of such approaches in his presentation on "Signaling Networks and Coordinated Regulation of Cellular Responses." In secretory cells, the activity of intracellular machines, involved in a transcriptional or translational apparatus, must be controlled to optimally respond to extracellular signals. This is achieved by a signaling network that can receive, process, and integrate these signals and also can control different cellular machines. Localization of signaling events to a defined intracellular space contributes to the selective regulation of cellular machines. Using computational models and benchtop experiments, his team has investigated the MAP-kinase 1,2/protein kinase C network. They have shown that the system is flexibly designed to operate as either a monostable or bistable system, depending on the concentration of MAPkinase phosphatase. Brief stimulus with low concentrations of MAP-kinase phosphatase induces a bistable behavior and sustained MAP-kinase phosphatase activation, whereas higher levels of stimulus induce a monostable state, which regulates acute responses to stimulus without sustained activation. They also found that selective forms of the cAMP-phosphodiesterase type 4 (PDE4) can regulate the microdomains of cAMP concentrations in response to extracellular stimulation, which in turn regulate the activity of protein kinase A. It is the balance of MAP-kinase and protein kinase A effects PDE4 activities that define the boundaries of cAMP microdomains and the duration of local and distal protein kinase A action.
For a number of years, Melanie H. Cobb (Dallas, TX) and her team have investigated the regulation and function of MAP kinases in ␤ cells. She provided several lines of evidence supporting her conclusion that the MAP kinases ERK1 and ERK2 are important components of the signaling mechanisms that control homeostasis in ␤ cells. ERK1 and ERK2 contribute to both basal and glucose-stimulated insulin gene transcription. Of several transcription factors that bind to the insulin promoter, ERK2 phosphorylates the major insulin transcription factors Beta2/NeuroD1 and PDX1. Phosphorylation of Beta2 at serine 274 by ERK1 and ERK2 is required for its maximal transactivation activity in response to glucose. Similarly, PDX1 transactivation activity is reduced by mutating the 2 sites phosphorylated by ERK2 and by adding a MEK inhibitor. The mechanisms of ERK1 and ERK2 activation in ␤ cells appear to include a Ras family small G protein, B-Raf, and MEK1. ERKs are activated in a calcium-dependent manner even at subthreshold glucose concentrations, and GLP-1 also activates ERK2 through a PKA-dependent mechanism.
Morris F. White (Boston, MA) reported that insulinreceptor substrate proteins were involved in the development of ␤ cell dysfunction. Irs2 −/− knockout mice show insulin resistance, progressive glucose intolerance, ␤ cell loss and decreased islet insulin contents, followed by the development of overt diabetes. Overexpression of the Irs2 gene in the ␤ cells of normal mice has no effect on glucose metabolism, but increased glucose-stimulated insulin release islet cell mass and insulin content in vivo. Irs2 overexpression in the ␤ cells of Irs2 −/− knockout mice resulted in increased blood insulin levels, increased food intake and weight gain (up to 30%), and normal insulin tolerance. However, the mice remained insulin resistant. The Pdx1 expression in the pancreas decreased before the onset of diabetes in Irs2 −/− knockout mice as compared with that in wild-type or Irs1 knockout mice. The expression of Irs2 in the islets upregulated the Pdx1 level in both wild-type and Irs2 knockout mice. These results suggest that Pdx1 is regulated by the Irs2 branch of the insulin/IGF signaling system. Examination of Pdx1 gene dosage effects in Irs2 knockout mice have revealed that Pdx1 haploinsufficiency accelerates diabetes onset (newborn versus 8-10 weeks), while transgenic expression of Pdx1 restores the ␤ cell mass and function and prevents the onset of diabetes. Thus, Dr. White suggested that dysregulation of Pdx1 expression by functional mechanisms might be one of the common links between ordinary type 2 and MODY diabetes.
␤ CELL BIOLOGY AND PROMOTION OF ␤ CELL GROWTH
Daniel Pipeleers (Brussels, Belgium) overviewed several lines of ongoing research at the Diabetes Research Center of the Free University of Brussels. Their studies, using single ␤ cell preparations, showed a high heterogeneity in response to glucose challenge. Glucose responsiveness was also found to be age-dependent and ␤ cells from donors older than 50 years of age showed significantly diminished insulin responses. Such age-related changes may be associated with amyloid deposit and lipid droplets in the islet cells. In the discussion of their islet isolation results, Dr. Pipeleers mentioned the presence of a considerable number of insulin-positive cells scattered as small cell clusters, some of them in association with ductal structures, which were usually lost after islet purification. He also explained the role of ductal cells in ␤ cell neogenesis based on their observation of insulin-positive cells emerging from the duct epithelia when islets were transplanted into athymic mice.
Several other speakers discussed the presence of ␤ cell precursors in the pancreatic duct epithelium and their role in generation of ␤ cells. Riccardo Perfetti (Los Angeles, CA) observed, both in vitro and in vivo, ␤ cell neogenesis from the duct epithelium in islet culture and islet recipients treated with glucagon like peptide-1 (GLP-1). He illustrated the effect of GLP-1 on islet-cell regeneration, as well as on the inhibition of ␤ cell apoptosis. Based on these findings, he suggested that the increased ␤ cell mass mediated by GLP-1 is due to a combination of its effect as a growth factor and apoptosis inhibitor. His studies have also shown that GLP-1 enhances the transcription of various genes, including insulin, glucose transporter, and hexokinase-1 and also increases insulin secretion in a glucose-dependent fashion. In vivo, GLP-1 has been shown to improve ␤ cell function in aging and obese animals.
Aaron I. Vinik (Norfolk, VA) discussed a factor that induces islet stem cell differentiation. INGAP, a factor recognized in their earlier investigation on regenerating pancreatic tissue in the hamster, is found to improve and/or reverse STZinduced diabetes in rats. A 15-amino-acid sequence within INGAP is identified as a biologically active core that stimulates ductal cell proliferation and differentiation into ␤ cells. INGAP is also thought to prevent ␤ cell apoptosis.
Alberto Hayek (LaJolla, CA) discussed his team's work on islet proliferation from human fetal pancreata and adult islets. Endocrine cells in the human fetal pancreas have been shown to develop from Ngn3-positive cells, and cells costained with glucagon and insulin are often detected in duct epithelia. During normal development, insulin-positive cells migrate from the duct, aggregate, and form islets. In Dr. Hayek's laboratory, islet-like cell clusters (ICC) were constructed by aggregating fetal pancreatic cells prepared by enzymatic dissociation. Twenty percent to 25% of ICCs constructed from a 16-to 20-week pancreas are endocrine cells, and the remaining 60% to 70% are undifferentiated cells. Dr. Hayek's group found that, in vitro, fetal cells did not survive even with the help of various growth factors, but in vivo in athymic mice, ICCs continued to differentiate. After 3 months in athymic mice, the insulin content of the ICC graft became equivalent to that of adult islets. However, despite their ability to grow, mature, and perhaps acquire normal function, Dr. Hayek pointed out that fetal ICCs do not meet the current FDA regulation in 2 areas: (1) multiple donors are required to construct sufficient ICCs for glycemic control and (2) fetal ICCs are incapable of responding to high glucose with insulin release at the time of transplantation.
To promote functional maturation of ICCs in vitro, his team tested a variety of growth factors and culture methods, but without success. Nicotinamide clearly promotes ICC differentiation but the effect is insufficient; betacellulin increases precursor proliferation; activin enhances ␤ cell differentiation but without effect on functional maturation; exendin-4 increases PDX1 expression but has no effect on insulin production. However, when ICC recipients were treated for 10 days, exendin-4 significantly increased ␤ cell mass and shortened the period required for functional maturation of fetal ␤ cells.
Thus, ICCs in the exendin-4 treated mice released insulin in response to high glucose stimulation 8 weeks after transplantation, approximately 4 weeks earlier than the untreated controls. Unlike fetal ICCs, adult human islets cells grew well in monolayers when hepatocyte growth factor (HGF) was added to the culture medium, but the insulin expression was lost in the replicated cells. Even when monolayer-grown cells were aggregated, these cells failed to express insulin in vitro or in vivo following transplantation.
In the search for ␤ cell precursor marker(s), Dr. Hayek's team has conducted a series of investigations using fetal human pancreata to determine whether nestin is a potential candidate marker. Their results provide several lines of undeniable evidence demonstrating that nestin is not a marker for ␤ cell precursors. In the human fetal pancreas, nestin does not colocalize with insulin. Nestin is totally negative in pancreatic epithelial cells, and its expression is only found in the associated mesenchyma. To further confirm this, the team isolated a pure population of nestin-positive cells from a 24-week pancreas, expanded them ex vivo, and then used the cells to construct ICCs. These ICCs were transplanted into athymic mice and removed after 12 weeks. Mice were bled at the time of graft removal for human C-peptide testing. Immunostaining revealed the total absence of endocrine cells, and no C-peptide was detected in the blood. These results demonstrate that nestin is not a marker for pancreatic endocrine cells.
RECENT PROGRESS IN ␤ CELL GENERATION FROM STEM CELLS AND BY BIOENGINEERING
One of the major problems that will prevent the application of islet transplantation in a wider range of type 1 diabetic patients is clearly the shortage of donor islets. Generating renewable sources of ␤ cells is 1 solution for this problem. In this context, the use of either embryonic or adult stem cells represents an interesting alternative.
Bernat Soria (Alicante, Spain), one of the leading investigators in this field, presented several approaches that have been used to differentiate stem cells into insulin secreting cells, with special focus on the "gating technology" used in their laboratory. He stated that the key is knowing how to reprogram the information of the nuclei and how to select cells expressing a desired phenotype. Because of their plasticity, embryonic stem cells (ESCs) need to be coerced into becoming a certain cell type. The method used in Dr. Soria's laboratory was to first generate ESC lines and then transfect them with a construct that expresses the neomycin selection system under the control of the regulatory regions of human insulin gene. The construct also contains a hygromycin resistance gene under the control of the constitutive phosphoglycerate kinase promoter to allow the selection of single clonal ESC during the expansion stage. The selection strategy was combined with a final maturation process in Petri dishes to form cell aggregates. Lowering glucose concentration and adding nicotinamide during this stage
Advances in Islet Cell Biology were instrumental for phenotypic changes. Clones producing variable amounts of insulin were obtained, but only 1% of approximately 800 clones showed any insulin production and only 2 clones produced as much as 0.5-0.8 ng insulin/µg of protein. When aggregates were implanted into the spleen of STZ-diabetic athymic mice, the best insulin-containing clone reversed hyperglycemia in approximately half of the recipients and the transplanted cells were detected in the spleen and liver. Thus, the principle of their method was shown to work. Strategies similar to their method were used by other investigators for stem cells from bone marrow, endoderm, and human intestinal epithelia with certain amounts of success. Dr. Soria concluded that increasing the insulin production in higher numbers of clones was the next major problem to be solved. Development of surrogate ␤ cells using bioengineering techniques is another potential source for cell therapy for diabetes. Christopher B. Newgard (Durham, NC) is a pioneer in this field and has conducted a series of investigations for the purpose of obtaining detailed information of ␤ cell function as a prerequisite for the development of surrogate ␤ cells. In this symposium, he discussed the studies conducted by an interdisciplinary approach, focusing on the biochemical mechanisms that increase insulin secretion in response to metabolic fuel and that protect ␤ cells from immune destruction. Using INS-1 cell lines with different glucose responsiveness, these investigators have shown differences in the expression profiles of a series of genes, an important role for pyruvate carboxylase-mediated pyruvate cycling pathways for glucose-stimulated insulin release, and specific impairment of pyruvate cycling in islets exposed to elevated lipid concentrations. To identify genes that protect islets from the toxic effect of cytokines and/or reactive oxygen species (ROS), Dr. Newgard and his team exposed INS-1 cells for an extended period to the cytokines IL-1␤ and IFN-␥ to select particular resistant cell populations. Then, specific genes expressed by the resistance cell populations were determined. Bcl-2 was found to provide clear protection against cytotoxicity mediated by ROS but relatively poor protection against cytokine damage. Cells selected by the cytokine-selection procedure were protected strongly against cytokines and weakly against ROS. When bcl-2 expressing cells were exposed to the cytokine selection procedure, the selected cell lines gained protection against both ROS and cytokines. These results suggested that the selection process resulted in cytokine resistance via a different pathway independent of the presence or absence of background bcl-2 expression. The cytokine-selected cells without bcl-2 expression strongly suppressed the iNOS expression and NO production in response to cytokines, while this suppression did not occur in the selected cells with bcl-2 overexpression.
Pamela R. Itkin-Ansari (La Jolla, CA) reported on the genetically engineered pancreatic endocrine cell lines developed in her laboratory. These cell lines were generated to express growth stimulatory genes using cultured adult human ␤ cells. These cells proliferated indefinitely, but growth stimulatory genes had an adverse effect on differentiated cell function. Restoration of ␤ cell differentiation was achieved in 1 cell line by expressing PDX1 and stimulating multiple signaling pathways through cell-cell contact and the GLP-1 receptor. This cell line was able to restore ␤ cell function and reverse STZ-induced diabetes in athymic mice. 5 In a cell line developed from fetal islets, the expression of PDX1 and cell aggregation led to somatostatin expression, 6 but subsequent overexpression of NeuroD1 in these cells induced insulin gene expression. These results indicated that PDX1 and NeuroD1 act in synergy on native chromatin to promote insulin gene expression. In addition, the IAPP gene, which was not a known downstream target of NeuroD1, was also induced. NeuroD1 suppressed somatostatin expression, reminiscent of the switch in hormone expression during islet regeneration in vivo, where NeuroD1 is localized in ␤ cells but not in ␦ cells. Thus, results have suggested that NeuroD1 may be a component of a gene expression and/or transcription factor cascade that is involved in hormone switching and terminal differentiation of endocrine cells. The team has used this model for studying mechanisms and manipulation of endocrine cell fate in the human pancreas.
ADVANCES IN UNDERSTANDING DIABETES AUTOIMMUNITY
Type 1 diabetes is an autoimmune disease tightly associated with the HLA class II genes and the presence of antibodies against self-antigens. Both CD4 and CD8 cells are involved in the pathogenesis of the disease, but the mechanisms of disease pathogenesis have remained obscure. However, it is known that type 1 diabetes is regulated by the genetic background of individuals and by the environment. Linda S. Wicker (Cambridge, UK) presented her studies on the search for potential genes involved in the development of diabetes in NOD mice, an extensively studied mouse model for the human disease. Many such susceptibility genes, termed Idd genes, have been assigned to specific regions of the genome. Transgenic NOD mice expressing the Idd3 or Idd5 genes have reduced insulitis and are able of restoring self-tolerance. Idd3 expression also reduces the development of autoantibodies directed against insulin and islets and increases transplantation tolerance. The candidate genes for Idd5.1 are the ctla4 or icos genes, both encoding for molecules that are critical to the function of T cells. Interestingly, it seems that sequence variations of the ctla4 gene exist between susceptible and resistant mouse strains, which may alter the expression of ctla4 isoforms produced during immune responses. Other candidate Idd genes, such as 4-1BB, FRAP, and Idd10, may also be involved in the normal function of T cells. Idd gene identification may increase the chances of finding 1 or more targets for therapies. It is also likely that combination therapy that involves targeting more than 1 critical pathway leading to diabetes could hold the most promise in treating or preventing the disease.
ISSUES IN CLINICAL ISLET TRANSPLANTATION
Since 1993, pancreatic islet and other types of somatic cell therapy have become the subject to regulation by the U.S. Food and Drug Administration (FDA) as biologic products. 7 The new era of islet transplantation also has brought increased grant support by the National Institutes of Health (NIH) and Juvenile Diabetes Research Foundation (JDRF) for both islet isolation and clinical procedures. The NIH also supported the development of a Collaborative Islet Transplantation Registry (CITR) for collection of clinical transplantation data and has supported the development of a national program for islet isolation and distribution for clinical transplantation trials termed Islet Cell Resources (ICR) Centers. Ten such centers were funded in 2001. Program officers were invited to cover these areas in clinical islet transplantation.
Regulatory Issues in Clinical Islet Transplantation
The FDA has published its expectations in detail regarding investigational new drug (IND) application for allogeneic islets.
8 Darin J. Weber from the Division of Cellular and Gene Therapies and Division of Biologic Evaluation and Research (CBER) of the FDA (Rockville, MD) discussed the regulatory issues that the FDA had encountered in the review process of more than 30 IND applications submitted for islet transplantation. Many of these IND applications had been placed on "clinical hold." The hold for a phase 1 clinical study means that a given islet IND submission was considered deficient in safety information in 1 or more areas, such as manufacturing, preclinical data, and/or clinical protocol design. Common reasons included (1) failure to submit data on the preparation of high quality islets, (2) lack of data supporting preclinical data for novel combinations of immunosuppressive drugs or sites of implantation, and (3) deficiency in following good clinical practices (GCP). The FDA has been taking a flexible "stepwise" approach for the application of the regulatory requirements. Since safety is of vital importance in a phase 1 study, the assurance of aseptic manufacturing and appropriate microbiological safety testing is imperative. Assuming safety considerations are appropriately addressed, it is not obligatory to prepare the product in a facility that is fully compliant with the current good manufacturing practices (cGMP), nor is it expected that the product will be fully characterized or that the manufacturing process will be optimized prior to the phase 1 study. Since the products are still under development in the IND process, it is expected that the manufacturing process will continue to be optimized, methods to fully characterize the product will be undertaken, and product specifications will be refined based on data collected. For early-stage clinical studies, changes to the manufacturing process are acceptable when they are minor and are likely to improve the safety without changing the inherent characteristics of the final product. For more significant changes, such as moving from a fresh product to one that has been cultured, the FDA may ask that a new IND application be submitted. When changes in product manufacturing are proposed, data should be available to clearly demonstrate how the changes affect the final product prepared under the different processes, in regulatory parlance referred to as "product comparability." The FDA also recognizes that some flexibility in islet preparation protocols may be necessary due to the inherent variability of donor pancreata. However, it is imperative that islet IND sponsors collect sufficient manufacturing data during ongoing clinical studies to demonstrate product comparability. As product development and clinical trials advance, increased compliance with lot release testing, product characterization and cGMP requirements must be implemented. Issues associated with islet preparation must be resolved prior to the submission of a biologics license application (BLA). It is expected that only a single, well-defined manufacturing process supported by data will be chosen that meets established lot release specifications by the time a BLA is submitted.
Thomas Eggerman (Bethesda, MD) from the National Institute of Diabetes and Digestive and Kidney Diseases explained the mission of the NIH-supported national Collaborative Islet Transplantation Registry. CITR was established in September 2001, to expedite and promote the progress and safety in islet and/or ␤ cell transplantation through the collection, analysis, and communication of comprehensive and current data on all islet and/or ␤ cell transplantations performed in the United States and Canada. The coordinating center is located at the EMMES Corporation, which provides support for logistics, data capture, quality control monitoring, statistical design and analysis, and other registry activities. Inclusion of the word "collaborative" in the name of the registry emphasizes the importance of collaboration among all areas that have a connection to islet transplantation, including collaborations (1) among transplant centers; (2) with other initiatives, programs, and networks of the National Institutes of Health, e.g., the Human Pancreatic Islet Cell Resource, the Immune Tolerance Network, U.S. Pancreas Transplant Registry, and the Juvenile Diabetes Research Foundation; (3) with the diabetes care community, the health insurance industry, the Centers for Medicare and Medicaid Services, Health Resources and Services Administration, and the FDA; (4) with United Network for Organ Sharing (UNOS) and the Canadian Organ Replacement Register (CORR); and (5) with Islet Transplant Registry (ITR) in Giessen. Dr. Eggerman also talked about membership criteria, CITR organization, and the progress made in the development of web-based forms for data collection, including the CITR Internet Data Entry System for quality control checks. CITR took steps to avoid duplication of efforts at the Transplant Centers, such as data on U.S. cadaver donors that could be directly imported from UNOS, and developed a short Retrospective Summary Form to capture islet transplant data performed between January 1996 and December 1998 to fill the gap between data collected by the ITR and CITR. CITR also closely works with the Coordinating Center for the 10 ICR Centers sponsored by the National Center for Research Resources, where detailed data on islet isolation and processing techniques are expected to be collected. CITR also assists the U.S.-based sites in making use of the resources provided by the General Clinical Research Center (GCRC) program of the National Center for Research Resources (NCRR) to develop inhouse islet transplant databases and to facilitate data transfers between the center and CITR. CITR invited 17 transplant centers to register that are either currently performing or plan to perform islet transplantation.
Richard Knazek from the National Center for Research Resources (Bethesda, MD) explained the role of NCRRsupported Islet Resources Centers in the advancement of islet transplantation. The Islet Cell Resources Centers are funded by the NIH and JDRF and comprise an interactive group of academic laboratories charged with the pursuit of 2 major goals: (1) to provide pancreatic islets to investigators for use in FDA-and IRB-approved clinical transplantation and (2) to optimize the harvest, purification, function, storage, and shipment of islets and to develop tests that characterize islet quality and predict the effectiveness of islets after transplantation into diabetic patients. The ICR Steering Committee reviews and approves applications for the use of islets in clinical transplantation trials and allocates the supply of islets to investigators based on the scientific merit and feasibility of proposed studies. Investigator eligibility for receipt of ICR islets and contact information are detailed in the ICR Policy and Procedures document, which is available online (www.ncrr.nih. gov/clinical/cr_icr.asp).
Larry A. Couture (Duarte, CA) discussed issues involved in designing and operating a multibiotherapeutic product facility in an academic environment through his extensive experience with the Center for Biomedicine and Genetics (CBG) facility at the City of Hope National Medical Center. The CBG is a 22,000-square foot manufacturing facility that comprises 3 production zones of 12 production rooms and suites and a variety of support areas. This facility currently serves as the islet production site of the Southern California Islet Cell Resources Center and also contains sites for other clinically ready activities including the production of plasmid DNA, adenoviral vectors, monoclonal antibodies or other recombinant proteins, and for ex vivo cell manipulations. Dr. Couture emphasized that academic institutions should be able to establish the infrastructure to allow translation of virtually any biotherapeutic technology from the bench-side into the clinical setting without primary regard for size of patient population, market viability, or other factors critical to the commercial enterprise operation.
Update in Islet Isolation and Culture Technologies
Rodolfo Alejandro (Miami, FL) reviewed the islet isolation process step by step and pointed out new technologies that have recently been introduced. For pancreas preservation, the 2-layer method, developed for cold storage of the pancreas by Yoshikazu Kuroda and his colleagues at the Kobe University 9 has been shown not only to preserve better islets but also assist in the recovery of islets from stress. 10 This method preserves harvested pancreata for longer periods, permits shipment of a donor organ from a distant site, and also provides some flexibility in the isolation schedule. In Miami, pancreata shipped in University of Wisconsin solution was often transferred and maintained by the 2-layer method for an extended period before initiating islet isolation. Their collaboration with the Islet Transplant team at the Baylor College of Medicine in Houston, TX, is a good example of the advantages provided by this method. Another major reason for the success is the assignment of a single surgeon to the organ procurement and thus emphasis on the importance of organ harvesting and handling procedures. Dr. Alejandro also described Miami's experience of significant lot-to-lot variability of Liberase, the enzyme solution used for pancreas digestion, and said that it is difficult to identify good lots. The Miami group uses 70,000 U/vial of neutral protease and 2000 Wunsch U/vial as a guideline for the selection. Although the concept of the islet isolation process has remained the same, there are different preferences in almost every step of islet processing from 1 center to another and 1 investigator to another. For example, there are various opinions on the addition of DNase and/or Pefabloc to the Liberase solution, using a syringe versus the perfusion method for pancreas distention, processing the whole pancreas versus sectioned tissue for digestion, using manual versus machine shaking in the digestion process, using discontinuous versus continuous gradient centrifugation for islet purification, and using OptiPrep (Accurate Chemical & Scientific Co., Westbury, NY), a new reagent for islet purification in the United States. In Miami, most of isolations require "islet rescue," involving a second discontinuous density gradient, following the first COBE purification.
11 Individual preference also extends to transplantation procedures, such as transplantation of fresh versus cultured islets and the use of a bag versus syringe for islet infusion into the portal vein.
The Memphis group originally developed a serum-free culture medium for human islets. A. Osama Gaber (Memphis, TN) explained that the purpose of culturing islets is to develop technology that permits the collection of islets from all available pancreata, regardless of their quality and islet yields. Since pancreata rejected for whole organ or islet transplantation (discarded pancreata) are expected to be of poor quality and provide low islet yields, islets harvested for these organs must be accumulated by culturing or cryopreservation. In his center, the islet recovery after culture (>50% after 2-3 months) is better than those after cryopreservation. Islets cultured for extended periods stained faintly or negative for insulin and other hormones. However, when these islets were transplanted into SCID/NOD mice, 39 of the 58 grafts were viable with detectable amounts of C-peptides in recipient blood. Islets from discarded pancreata function better when transplanted after having been maintained in culture than if freshly transplanted. The tradeoff of culturing islets is a slow recovery of function in vivo, after transplantation. Dr. Gaber reported the reversal of diabetes was achieved in all cases with islets cultured for 1 month and over 70% with those cultured for longer periods.
Pre-and Post-transplantation Islet Quality
Islet transplantation success depends greatly on the health of the ␤ cells. Gordon C. Weir (Boston, MA) reported on the potential damage to islets and/or ␤ cells throughout the islet transplant process. Like many other investigators, Dr. Weir noticed that some assays used for the assessment of islet quality were inadequate, and standardized assessment methods were necessary for prediction of posttransplantation islet performance. His isolation center routinely performs morphologic studies of 500-800 islets using light microscopy or electron microscopy. These studies provide valuable and interesting information, such as distorted mitochondria, presence of lipid droplets and amyloid deposit, and differences in ␤-and non-␤ cell ratio. Measurements of oxygen consumption (O 2 /DNA) by islet preparations have also shown some promise. He suggests that proteonomics, gene arrays (especially the detection of the key stress gene expression), nuclear magnetic resonance, calcium imaging, and mitochondrial membrane potential measurements are also potentially useful tools for islet evaluation. Islet damage during transplantation is primarily due to hypoxia, glucose toxicity, and the generation of inflammatory products. Hyperglycemia increases oxygen consumption, and a loss of small vessels and delayed angiogenesis accelerates hypoxia. Chronic hypoxia may also reduce ␤ cell numbers. In islet transplants, the normal intraislet cell-cell relationships (such as ␣ cells residing downstream of the blood supply from ␤ cells) may be destroyed, causing altered insulin secretory responses to glucose. Transplanted ␤ cells under stress would also be subject to glucose toxicity, since the gene expression profiles of ␤ cells are known to change under stress. Such changes would likely contribute to a reduction in glucose responsiveness and an increased susceptibility to apoptosis. Dr. Weir suggested the use of arginine stimulation tests for assessing post-transplantation ␤ cell functional assessments.
Arne Andersson (Uppsala, Sweden) also pointed out the importance of developing strategies to reduce harmful events on transplanted islets. He suggested that treatment with growth factors would be an effective method for increasing ␤ cell mass in the graft, and in vitro studies provide useful screening methods for selecting growth factors for in vivo studies. He produced data on graft site-dependent factors, which control posttransplantation graft growth, and donor age-dependent ␤ cell replication. Following transplantation, endothelial cells in the islets dedifferentiate. The nerve cells, which initially survive, eventually disappear and are replaced mainly by sympathetic nerves located along the newly formed blood vessels. Previous studies have shown that grafted islets revascularize and that the density of newly formed blood vessels is similar to that in the endogenous islets. However, Dr. Andersson's team found that the newly formed vessels were mostly located around the islets in the connective tissue separating islets from each other, with very few vessels found inside of the islets. In the pancreas, the oxygen pressure in the islets is double that of the exocrine parenchyma. Immediately after transplantation, under the kidney capsule, the oxygen pressure in mouse (and human) islets is about 25% of that measured in native islets and remains at this level for over 6 months. Under hyperglycemia, the oxygen pressure is shown to further decrease. Although hyperglycemia and hypoxia per se can increase insulin mRNA levels in cultured islets, the graft vascular dysfunction and hypoxia may likely lead to some metabolic dysfunction or functional alteration of transplanted islets. Using a microdialysis technique, the grafted islets display an increased degree of anaerobic metabolism, 3 times higher than that of cultured islets, as detected in his studies.
Recent Progress and Future Issues in Clinical Islet Transplantation
Bernhard J. Hering (Minneapolis, MN) updated the results of the NIH Immune Tolerance Network trials and discussed new developments in immunosuppressive regimens that may have potential in islet transplantation. Since 1999, 29 islet allografts were performed by 9 institutions of the ITN. All but 2 grafts have lowered insulin requirements, and 25 patients are insulin free for more than 1 year. The total islet numbers used for transplantation ranged from 8000 to 15,000 IEQ/kg of recipient body weight. Among the 25 patients, 5 received islets from a single donor and the remaining from 2 to 3 donors. The use of the 2-layer method for pancreas preservation and cultured islets for transplantation has become a common procedure. Since islet autotransplants with >300,000 IEQ have achieved over 15 years of insulin independence in depancreatectomized patients, islet allografts should work if optimal immunosuppressive regimens that have minimal adverse effect on islet function are developed to control allo-and autoimmune responses. Results first reported by the Edmonton group 2 and subsequently confirmed by other institutions indicate that sequential islet allotransplantation from 2 to 3 donors consistently reversed insulin dependency in type 1 diabetic recipients treated with a steroid-free immunosuppressive regimen that included interleukin-2 receptor antibody (dacli-zumab), sirolimus, and a reduced dose of tacrolimus. This regimen has been tested in all 9 ITN centers. Dr. Hering discussed a long list of newer agents as substitutions for diabetogenic calcineurin inhibitors, e.g., cyclosporin A and tacrolimus, that may be worth testing toward the goal of achieving restoration of insulin independence with single donor islet transplantation. Such nondiabetogenic agents should preferably work synergistically with sirolimus or everolimus. Candidate agents include mycophenolate mofetil, FTY720, CTLA4-Ig, LEA29Y, and anti-CD154 monoclonal antibody. Strategies that focus on peritransplant deletion or inhibition of autoreactive and alloreactive T cells as well as the inhibition of macrophage activation are necessary for enhancement of islet engraftment. Candidate agents for these purposes include the FcR nonbinding anti-CD3 antibody, hOKT3␥1 (AlaAla), polyclonal T-cell antibody and anti-CD52 monoclonal antibodies. A third strategy he suggested is peritransplant administration of inhibitors of inflammatory cytokines. Protocols to facilitate peripheral tolerance induction by temporary immunosuppression have been investigated to instigate activation-induced cell death of antidonor and anti-self T cells to induce regulatory T cells that control memory T cells and to monitor these critical events. Strategies for induction of central tolerance may become more feasible with costimulatory blockade and sirolimus. Although acute complications have been minor, the experience with newer protocols is limited and monitoring needs to be extended to assess long-term risks.
R. Paul Robertson (Seattle, WA) discussed metabolic issues in islet transplantation based primarily on clinical data obtained from islet autotransplantation. Since 1980, islet autotransplantations were successfully performed in patients with chronic, painful pancreatitis, following total pancreatectomy. In these patients, stable euglycemia was achieved with 300,000-500,000 IEQ showing that a half million islets are sufficient to maintain intact acute insulin responses to intravenous glucose challenge and normal levels of HbA1c for up to 16 years. Even 125,000 IEQ were able to induce partial but good glucose control, a number well below the estimated 8000 IEQ/kg currently required for allotransplantation in type 1 diabetes. Thus, the challenge in islet allotransplantation is to reduce the islet number required to achieve euglycemia to 500,000 IEQ. Possible reasons for such differences include preexisting autoimmunity, the use of cadaveric pancreata (involving long ischemic times), alloimmunity, and/or the use of immunosuppressive agents. He stated that the 2-layer pancreas preservation method could preserve and/or improve islet function as indicated by post-transplantation C-peptide levels obtained with a smaller islet mass. Dr. Robertson and his team measured ␣-cell function during hypoglycemia by step-clamp function tests in islet-transplant recipients. In both auto-and alloislet recipients, there was no increase in glucagon during hypoglycemia, despite the presence of glucagon in the hepatic venous blood (indicating the presence of ␣ cells in the grafts).
Similarly, negative glucagon responses were obtained in dogs transplanted with islets into the liver. In contrast, glucagon levels increased in dogs transplanted with islets into the peritoneal cavity. Epinephrine response did not improve in islet recipients with type 1 diabetes even after years of good glucose control. In contrast, type 1 diabetic patients transplanted with a whole pancreas showed good glucagon responses and attenuated epinephrine responses. This raises a question about undetected hypoglycemic unawareness in islet transplant recipients. In addition, he pointed out that immunosuppressive agents are present in the liver at higher concentrations. Some of the existing results are inexplicable at present. Dr. Robertson also raised the question of whether the liver is an optimal site for islet grafts.
Induction of Specific Immune Tolerance: Potential Approaches Developed in Animal Studies
Ali Naji (Philadelphia, PA) emphasized the importance of maintaining active, open-minded basic research for forecasting and solving emerging problems in clinical islet transplantation by referring to earlier animal studies that revealed a number of key issues in clinical islet transplantation. Dr. Naji pointed out that autoimmunity presents unique immunologic problems including (1) need for immunosuppressive regimens directed for both auto-and alloimmune responses, (2) major histocompatibility complex (MHC) compatibility between donor and recipient is beneficial for immune reaction directed against alloantigens but does not improve graft susceptibility to autoimmunity, and (3) the presence of autoantibodies influences graft survival. Culturing islets prior to transplantation is known to reduce islet immunogenicity and consequently the alloimmune reaction, but it would have little effect on autoimmune islet destruction. The thymus presents a microenvironment for islet survival and protection from both allo-and autoimmunity. The Philadelphia team is currently investigating intrathymic islet allotransplantation in a nonhuman primate model. Because autoimmune diabetes is T cell-mediated, the participation of B lymphocytes in the development of autoimmune diabetes has long been neglected. Dr. Naji suggested a potential role of B cells in antigen presentation, since diabetes develops in only a very low percentage (1 out of 400) of NOD B cell knockout mice.
The goal of transplant immunology is to induce specific immune tolerance for permanent survival of allografts. Soji F. Oluwole (New York, NY) discussed experimental strategies for tolerance induction that may have potential for clinical application. Mechanisms involving T-cell tolerance are divided into 2 categories: (1) central deletional tolerance and (2) peripheral tolerance, which includes strategies to mediate activation-induced cell death, anergy, immune deviation, and/or the induction of regulatory T cells. These mechanisms are not mutually exclusive. The introduction of donor antigens into the thymus of mice induces specific T-cell tolerance, but whether the adult human thymus can shape the T-cell repertoire in the same manner as the rodent thymus remains unclear. Mixed bone marrow chimerism allows the coexistence of both donor and recipient hematopoietic stem cells with minimal graft versus host disease incidence. The bone marrow stem cells migrate to the thymus where they mediate the deletion of both recipient-and donor-reactive T cells. In nonhuman primates, anti-CD-154 monoclonal antibody (MAB) combined with sublethal total body irradiation was shown to be a promising approach and may be used clinically. Although a nonmyeloablative protocol induces tolerance, it is also associated with the development of donor-specific alloantibodies that may lead to chronic graft rejection. The B7 molecules on antigen-presenting cells (APCs) and their ligands on T cells provide critical costimulation signals required for clonal expansion of specific T cells. Blockage of the CD28/B7 pathway using CTLA4-Ig has been known to prevent graft rejection, but no permanent graft acceptance has been achieved. The CD40/CD154 blockade induced islet allograft acceptance when combined with donor antigen pretreatment. However, this method was ineffective in NOD mice, and sublethal total body irradiation and bone marrow transplantation were also needed. Other mechanisms for costimulatory pathway blockage, i.e., CD28 or B7 (ICOS and B7RP-1) or tumor necrosis factor family member LIGHT, are also known to induce allospecific T-cell anergy. In nonhuman primates anti-CD-154 MAB was shown to be more effective than CTLA4-Ig. Two major problems associated with the use of anti-CD154 MAB are the generation of donor-specific alloantibodies and the development of thromboembolic complications. Moreover, additional donor cell treatment appears to be needed to provide adequate direct signaling via MHC molecules to achieve graft acceptance.
Dr. Oluwole also discussed critical roles played by dendritic cells (DCs) in central and peripheral tolerance. Since in the thymus T cell receptor (TCR)-MHC/self-peptide presented by self-DCs regulates T-cell development, a presentation of peptides by self-DCs to developing T cells or colonization with donor DCs in the thymus induces acquired thymic tolerance. DCs are also key modulators of the immune responses that influence T cell differentiation. Immature myeloid DCs can induce allogeneic T cell hyporesponsiveness, while mature myeloid DCs induce robust allostimulatory responses. Adoptive transfer of donor-type immature myeloid DCs induces donor-specific regulatory T cells and prolongs allograft survival. Immature DCs may also stimulate the generation of effector T cells in vivo that involve the induction and maintenance of peripheral transplant tolerance via activation-induced cell death. Treatment with immature DCs was also shown to result in the generation of IL10-and transforming growth factor-␤−producing regulatory T cells. At present, no reports are available that have evaluated immature DCs therapy in a nonhuman primate model.
To control self-reacting T cells in the periphery, clonal deletion and anergy in the thymus is not sufficient. Several lines of new evidence suggest that the presence of a distinct immunoregulatory T cell is required to downregulate the activation and/or proliferation of self-reactive or allospecific T cells. These T cells express CD4, CD25, and CTLA-4 and arise from the thymus. CD4-and CD25-positive T cells, when stimulated via TCRs in vitro, suppress antigen-specific and polyclonal activation of other T cells. At least 2 mechanisms are involved in this suppressor function: (1) the regulatory T cell directly inhibits the functional state of APCs resulting in failure to engage other T cells and (2) the regulatory T cell inhibits IL2 production by blocking the costimulatory signal through direct cell-to-cell contact via TCRs. Dr. Oluwole concluded that clinical transplant tolerance is only possible with a deliberate introduction of donor antigens into the recipient combined with a short course of immunosuppression.
David Sharp (Irvine, CA) gave an overview of methods for immunoisolation of islets. He presented data demonstrating the advantages of polyethylene glycol (PEG) coating. PEG-coated allogeneic islets transplanted into pancreatectomized, nonhuman primates functioned over 55 days without additional immunosuppressants. Transplanted animals are off insulin, and the recovered capsules contained islets that stained for both insulin and glucagon. Work is also in progress using PEG-coated islets transplanted into STZ-induced diabetic nonhuman primates.
CONCLUSION
The 3rd Annual Levine Symposium, held in October 2002, presented an excellent comprehensive review of up-todate and newly generated data in the quickly developing field of islet biology and transplantation. The 3-day conference offered physicians and scientists with varying interests a thorough review of all aspects of the field. Topics covered at the conference included the latest information on pancreas and islet cell morphogenesis, insulin synthesis and secretion, the islet cell signaling network, stem cell differentiation, diabetic autoimmunity, islet isolation and culturing technologies, clinical islet transplantation, the efficacy of islet transplantation, and characterization of remaining metabolic abnormalities post-islet transplantation. Presentations and discussions helped highlight current advances in the above topics and defined future challenges facing scientists and clinicians who are dedicated to advancing the understanding of cellular development of the endocrine pancreas, pathophysiology of immunemediated ␤ cell destruction in type 1 diabetes, and the role of islet transplantation in the treatment of patients with this devastating disease. The recruitment of young scientists to attend this intensive review of available data and future challenges was made possible by the generous travel awards provided by the NCRR of the NIH and will undoubtedly help in the development of their careers. Generous support from the David Shapiro (a victim of type 1 diabetes) Research Fund and the American Diabetes Association helped personify the objectives of the 2002 Levine Symposium. The symposium provided a forum for leading scientists and clinicians to share ideas and form collaborations that will help accelerate the development of a long-awaited cure for type 1 diabetes.
The 4th Annual Levine Symposium will be held on November [4] [5] [6] [7] [8] 2003 , at the Sheraton Universal Hotel in Universal City, CA. The 4-day meeting will offer updates in type 1 and type 2 diabetes research and focus on cellular and physiological aspects of diabetes and its complications and the latest progress in metabolism and energy balance, obesity and macrovascular complications, oxidative stress and other mechanisms of diabetic complications, signal transduction and advanced glycation end products, diabetic nephropathy, ␤ cell biology, islet cell generation, islet immunology, and islet transplantation. The 2003 Levine Symposium will provide an opportunity for scientists interested in both type 1 and type 2 diabetes to interact and share ideas for the development and advancement of future therapeutic strategies to combat these life-threatening and epidemic diseases. Further information on the 2003 Levine Symposium can be found online (levinesymposium.coh.org).
